Serdiuk, Tetiana https://orcid.org/0000-0002-3706-5911
Redeker, Virginie https://orcid.org/0000-0003-2694-8388
Savistchenko, Jimmy
Neupane, Sandesh https://orcid.org/0000-0003-0677-8289
Haenseler, Walther
Fleischmann, Yanick
Reber, Viviane https://orcid.org/0000-0001-7653-6918
Keller, Sabrina https://orcid.org/0000-0002-8976-9208
Tiberi, Cinzia
Bachmann-Gagescu, Ruxandra
Gstaiger, Matthias https://orcid.org/0000-0002-3245-3253
Braun, Thomas
Riek, Roland
Gentleman, Steve https://orcid.org/0000-0002-7131-4643
Aguzzi, Adriano https://orcid.org/0000-0002-0344-6708
de Souza, Natalie https://orcid.org/0000-0003-4286-8951
Melki, Ronald https://orcid.org/0000-0003-0000-7096
Picotti, Paola https://orcid.org/0000-0002-4109-3552
Funding for this research was provided by:
Stiftung Synapsis - Alzheimer Forschung Schweiz AFS (2023-CDA02)
Fondazione Gelu
Association France Parkinson
Fondation pour la Recherche Médicale (ALZ201912009776)
Institut National de la Santé et de la Recherche Médicale
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (CRSII5_177195)
ETH Zürich Foundation
Parkinson Schweiz
EC | Horizon Europe | Excellent Science | HORIZON EUROPE European Research Council (866004)
ERA PerMed Era-Net Cofund (ANR-22-PERM-0006)
Personalized Health and Related Technologies (PHRT-506)
Peter Bockhoff Stiftung
EMPIRIS Foundation (2022-FS-353)
EU/EFPIA/OICR/McGill/KTH/Diamond Innovative Medicines Initiative 2 Joint Undertaking (875510)
EU/EFPIA/OICR/McGill/KTH/Diamond Innovative Medicines Initiative 2 Joint Undertaking (875510)
URPP AdaBD
Article History
Received: 19 May 2025
Revised: 31 January 2026
Accepted: 9 February 2026
First Online: 11 March 2026
Disclosure and competing interests statement
: PP is a scientific advisor for the company Biognosys AG (Zurich, Switzerland) and an inventor on patents licensed by Biognosys AG that cover the LiP-MS method used in this manuscript.